| Literature DB >> 35371923 |
Enas M A Mostafa1, Ayat M Tawfik2, Khadiga M Abd-Elrahman1.
Abstract
Paracetamol/Acetaminophen was widely used as a first-line antipyretic and analgesic for COVID-19 patients without giving any attention to the potential risk of related toxicities. A survey was conducted on 176 Egyptians using an online survey portal to assess their knowledge, and attitude regarding potential risk of paracetamol toxicities and whether COVID-19 pandemic affected their practices regarding safe use of paracetamol. The self-administered questionnaire was developed by the researchers and was validated by expert opinions. A pilot testing of the questionnaire was done. Alpha Cronbach test used to assess the internal consistency reliability of the survey revealed good reliability. Overall percent-score revealed that only 24.4% of participants had good knowledge about paracetamol and its related potential toxicities. 62.5% of participants considered paracetamol safer than other medications of the same indications. 42.6% of participants could advise others to use paracetamol without prescription. According to the participants' responses, physicians were less concerned to give instructions about possibility of overdosage. Our results also revealed that participants' administration of paracetamol without physician prescription was more during COVID-19. Practice of paracetamol administration more than the allowed number of tablets/day was significantly more evident during the pandemic. We concluded that the unsupervised use of paracetamol is an alarming sign that should be addressed as this could lead to a high rate of accidental paracetamol toxicity. A lesson learnt from COVID-19 pandemic is the need to implement behavior change measures to mitigate the risk of accidental paracetamol toxicity.Entities:
Keywords: ALF, acute liver failure; Acetaminophen; CFA, confirmatory factor analysis; COVID-19; COVID-19, Coronavirus disease 2019; Egyptians; FDA, Food and Drug Administration; MERS-CoV, Middle East respiratory syndrome coronavirus; NSAIDs, non-steroidal anti-inflammatory drugs; OTC, over the counter; PHC, primary health care; Paracetamol; REC, Research Ethics committee; ROS, reactive oxygen species; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation; Safe use; Toxicity; WHO, World Health Organization
Year: 2022 PMID: 35371923 PMCID: PMC8961937 DOI: 10.1016/j.toxrep.2022.03.035
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
General Knowledge regarding paracetamol among the studied participants (n = 176).
| Yes | 17(9.7) | ||
| 19(10.8) | |||
| Don’t know | 140(79.5) | ||
| Another paracetamol drug | 45(25.6) | ||
| No | 25(14.2) | ||
| Don’t know | 106(60.2) | ||
| Non-paracetamol drug | 56(31.8) | ||
| No | 27(15.3) | ||
| Don’t know | 93(52.8) | ||
| 64(36.4) | |||
| No | 12(6.8) | ||
| Don’t know | 100(56.8) | ||
| 32(18.2) | |||
| No | 15(8.5) | ||
| Don’t know | 129(73.3) | ||
| 19(10.8) | |||
| 5(2.8) | |||
| 19(10.8) | |||
| Jaundice | 5(2.8) | ||
| Change of urine color | 9(5.1) | ||
| Chest pain | 3(1.7) | ||
| No organ | 67(38) | ||
| 61(34.7) | |||
| Stomach | 14(8) | ||
| Kidney | 33(18.8) | ||
| Nerves | 1(0.6) | ||
| 40(22.7) | |||
| No | 18(10.2) | ||
| Don’t know | 118(67) | ||
Correct answers were written in bold and italic.
Knowledge regarding Paracetamol instructions of administration and total Knowledge % Score among the studied participants (n = 176).
| Don’t know | 44(25) | |
| 85(48.3) | ||
| More than the allowed no. | 35(19.9) | |
| Less than the allowed no. | 12(6.8) | |
| Don’t know | 52(29.5) | |
| 30(17) | ||
| More than the allowed time space | 90(51.1) | |
| Less than the allowed time space | 4(2.3) | |
| Don’t know | 37(21) | |
| 29(16.5) | ||
| More than the allowed no. | 5(2.8) | |
| Less than the allowed no. | 105(59.7) | |
| Mean± SD | 36 ± 15 | |
| Median (min-max) | 31.2(18.7–81.2) | |
| Poor | 31(17.6) | |
| Fair | 102(58) | |
| Good | 43(24.4) | |
Maximum number of tablets (500 mg tablet) per dose equivalent to 2 tablets.
Correct answers were written in bold and italic.
Minimum time space between doses (hours) equivalent to 4 hrs.
Maximum number of tablets (500 mg tablet) per day equivalent to 8 tablets.
General attitude regarding paracetamol among the studied participants (n = 176).
| 110 (62.5%) | 62(35.2%) | 4(2.3%) | ||
| 30(17%) | 51(29%) | 95(54%) | ||
| 54(30.7%) | 53(30.1%) | 69(39.2%) | ||
| 75(42.6%) | 25(14.2%) | 76(43.2%) | ||
Comparison of practice of paracetamol administration before and during COVID-19 pandemic among the studied participants (n = 176).
| With | 82(46.6) | 34(19.3) | ||
| Without | 94(53.4) | 142(80.7) | ||
| PHC, clinic, hospital | 65(79.3) | 15(44.1) | ||
| Telephone | 13(15.9) | 14(41.2) | ||
| Social media | 4(4.8) | 5(14.7) | ||
| Dose | 73(89) | 30(88.2) | ||
| Times/day | 66(80.5) | 31(91.2) | ||
| Duration | 47(57.3) | 16(47) | ||
| Side effects | 7(8.5) | 3(8.8) | ||
| Other as possibility of toxicity | 6(7.3) | 5(14.7) | ||
| Yes | 66(80.5) | 27(79.4) | ||
| No | 16(19.5) | 7(20.6) | ||
| Within or less than the allowed no. | 86(48.9) | 93(52.8) | ||
| More than the allowed no. | 90(51.1) | 83(47.2) | ||
| Within or less than the allowed time | 103(58.5) | 155(88.1) | ||
| More than the allowed time | 73(41.5) | 21(11.9) | ||
| Within or less than the allowed no. | 175(99.4) | 9(5.1) | ||
| More than the allowed no. | 1(0.6) | 167(94.9) | ||
*P-value is statistically significant.
Maximum number of tablets (500 mg tablet) per dose equivalent to 2 tablets.
Minimum time space between doses (hours) equivalent to 4 hrs.
Maximum number of tablets (500 mg tablet) per day equivalent to 8 tablets.
The relation between participants’ demographic characteristics and their knowledge (N = 176).
| 4(12.9) | 23(22.5) | 9(20.9) | |||
| 25(80.6) | 71(69.6) | 33(76.7) | |||
| 2(6.5) | 8(7.8) | 1(2.3) | |||
| 11(35.5) | 38(37.3) | 20(46.5) | |||
| 20(64.5) | 64(62.7) | 23(53.5) | |||
| 1(6) | 6(5.9) | 2(4.7) | |||
| 21(67.7) | 74(72.5) | 32(74.4) | |||
| 9(29) | 22(21.6) | 9(20.9) | |||
| 26(83.9) | 95(93.1) | 37(86) | |||
| 5(16.1) | 7(6.9) | 6(14) | |||
| 0(0) | 1(1) | 0(0) | |||
| 25(80.6) | 89(87.3) | 37(86) | |||
| 6(19.4) | 12(11.8) | 6(14.3) | |||
Association between participants’ practices of paracetamol administration before and after COVID-19 Pandemic and their knowledge (N = 176).
| Practice of paracetamol administration | Before COVID-19 Pandemic | After COVID-19 Pandemic | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Max. no. of tablets per dose | 29 | 88 | 38 | 17 | 46 | 20 | |||
| 2 | 14 | 5 | 14 | 56 | 23 | ||||
| Time space between doses (hours) | 21 | 45 | 20 | 1 | 3 | 5 | |||
| 10 | 57 | 23 | 30 | 99 | 38 | ||||
| Max. no. of tablets per day | 31 | 101 | 43 | 13 | 63 | 27 | |||
| 0 | 1 | 0 | 18 | 39 | 16 | ||||